A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-α Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren's Syndrome.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs GSK 2618960 (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline Research & Development
- 23 Aug 2017 Planned initiation date changed from 22 Aug 2017 to 5 Sep 2017.
- 01 Aug 2017 Planned End Date changed from 21 May 2019 to 8 Jun 2020.
- 01 Aug 2017 Status changed from recruiting to not yet recruiting.